Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

growth agriculture pty ltd - alkylaryl polyoxyethylene - glycol phosphate ester - liquid - alkylaryl polyoxyethylene - glycol phosphate ester petroleum derivative-oil active 794.0 g/l - adjuvant - adjuvant - acidifier | anti-crusting agent for soils | compatibility agent | cotton spindle cleaning | spray systems maintenance | surfactant | tank cleaning | callenberg spray system | conventional spray system | electrostatic spray system | lines | mixes of foliar sprays | mixes of herbicides | mixes of pesticides | nozzles | screens | to lower ph

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

miller chemical & fertilizer (australia) pty ltd - alkylaryl polyoxyethylene - glycol phosphate ester - liquid - alkylaryl polyoxyethylene - glycol phosphate ester petroleum derivative-oil active 780.0 g/l - adjuvant - agricultural chemical additive | herbicide additive | activator | penetrant | post emergent herbicide | spray activator | spread - acidifier | spreading agent | tank mixing | wetting agent (use as directed) | additive | agricultural chemical | herbicide | improve penetrating properties | minimise antagonism | spray tank | to lower ph

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - amino acid chamber alanine arginine aspartic acid cysteine dab glutamic acid glycine histidine isoleucine leucine lysine monohydrate dab methionine ornithine hydrochloride dab phenylalanine proline serine taurine threonine tryptophan, l- tyrosine valine potassium acetate calcium chloride dihydrate magnesium acetate tetrahydrate sodium glycerophosphate, hydrated glucose chamber glucose monohydrate lipid chamber olive oil, refined soya bean oil, refined ph. eur. - emulsion for infusion

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sm pharmaceuticals sdn. bhd. - insulin glargine__ -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - spironolactone, quantity: 100 mg - tablet, film coated - excipient ingredients: macrogol 400; maize starch; hypromellose; calcium sulfate dihydrate; povidone; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; iron oxide red; industrial methylated spirit; flavour - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome; diagnosis and treatment of primary hyperaldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate, hirsutism. essential hypertension: aldactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. aldactone improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. aldactone enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators etc. congestive cardiac failure: aldactone, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. aldactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics aldactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics aldactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalized patients since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema: aldactone when used alone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. aldactone provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics thus avoiding possible precipitation of hepatic coma. nephrotic syndrome : although glucocorticoids, whose anti inflammatory activity appears to benefit the primary pathologic process in the renal glomerulus, should probably be employed first, aldactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism: aldactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. aldactone may also be used for the short term pre operative treatment of patients with primary hyperaldosteronism, long term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and the long term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females: aldactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of aldactone should be considered only after all other alternatives of non drug therapy have been explored. for women of child bearing age, see contraindications and precautions, use in pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - spironolactone, quantity: 25 mg - tablet, film coated - excipient ingredients: macrogol 400; hypromellose; maize starch; calcium sulfate dihydrate; magnesium stearate; povidone; flavour; titanium dioxide; purified water; iron oxide yellow; iron oxide red; industrial methylated spirit - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome; diagnosis and treatment of primary hyperaldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate, hirsutism. essential hypertension: aldactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. aldactone improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. aldactone enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators etc. congestive cardiac failure: aldactone, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. aldactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics aldactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics aldactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalized patients since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema: aldactone when used alone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. aldactone provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics thus avoiding possible precipitation of hepatic coma. nephrotic syndrome : although glucocorticoids, whose anti inflammatory activity appears to benefit the primary pathologic process in the renal glomerulus, should probably be employed first, aldactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism: aldactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. aldactone may also be used for the short term pre operative treatment of patients with primary hyperaldosteronism, long term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and the long term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females: aldactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of aldactone should be considered only after all other alternatives of non drug therapy have been explored. for women of child bearing age, see contraindications and precautions, use in pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - spironolactone, quantity: 100 mg - tablet, uncoated - excipient ingredients: sunset yellow fcf aluminium lake; maize starch; povidone; magnesium stearate; peppermint oil; sodium starch glycollate; purified talc; erythrosine aluminium lake; polysorbate 80; quinoline yellow aluminium lake; lactose monohydrate; microcrystalline cellulose - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver and nephrotic syndrome; diagnosis and treatment of primary aldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate; hirsutism. essential hypertension. spironolactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. spironolactone improves the hypotensive action of thiazide diuretics, while at the same time reducing or preventing potassium loss due to the thiazide. spironolactone enhances the effectiveness of other antihypertensive agents such as beta-blockers, vasodilators, etc. congestive cardiac failure. when used alone, spironolactone is effective in the management of oedema and sodium retention associated with congestive cardiac failure. spironolactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics, spironolactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics, spironolactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalised patients, since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema. when used alone, spironolactone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. it provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics, thus avoiding possible precipitation of hepatic coma. nephrotic syndrome. although glucocorticoids, whose anti-inflammatory activity appears to benefit the primary pathological process in the renal glomerulus, should probably be employed first, spironolactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism. spironolactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. spironolactone may also be used for the short-term preoperative treatment of patients with primary hyperaldosteronism, long-term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females. spironolactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of spiractin should be considered only after all other alternatives of non-drug therapy have been explored. for women of childbearing age, see contraindications and use in pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - spironolactone, quantity: 25 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; peppermint oil; purified talc; sodium starch glycollate; lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate; polysorbate 80; sunset yellow fcf aluminium lake; erythrosine aluminium lake; maize starch - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver and nephrotic syndrome; diagnosis and treatment of primary aldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate; hirsutism. essential hypertension. spironolactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. spironolactone improves the hypotensive action of thiazide diuretics, while at the same time reducing or preventing potassium loss due to the thiazide. spironolactone enhances the effectiveness of other antihypertensive agents such as beta-blockers, vasodilators, etc. congestive cardiac failure. when used alone, spironolactone is effective in the management of oedema and sodium retention associated with congestive cardiac failure. spironolactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics, spironolactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics, spironolactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalised patients, since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema. when used alone, spironolactone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. it provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics, thus avoiding possible precipitation of hepatic coma. nephrotic syndrome. although glucocorticoids, whose anti-inflammatory activity appears to benefit the primary pathological process in the renal glomerulus, should probably be employed first, spironolactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism. spironolactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. spironolactone may also be used for the short-term preoperative treatment of patients with primary hyperaldosteronism, long-term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females. spironolactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of spiractin should be considered only after all other alternatives of non-drug therapy have been explored. for women of childbearing age, see contraindications and use in pregnancy.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - metsulfuron-methyl - water dispersible granule - metsulfuron-methyl urea-sulfonyl active 600.0 g/kg - herbicide - barley | cereal rye | commercial/industrial land | domestic and/or public area | flood plain | natural pasture (native) | pastur - african turnip weed | alligator weed | amsinckia | annual clovers | apple box | australian or native blackthorn | ball mustard | bellyache bush | bitou bush or boneseed | black bindweed | blackberry | blakely's red gum or gum | boggabri weed | bracken | bridal creeper | broadleaf dock | calomba daisy | cape tulip | capeweed | charlock | chickweed | chicory | climbing buckwheat | crofton weed | cutleaf mignonette | darling pea | deadnettle | denseflower fumitory | dock | erodium spp. | fennel | furze or gorse | golden dodder | great mullein | hare's-ear or treacle mustard | harrisia cactus | hawthorn | indian hedge mustard | inkweed | japanese sunflower | kangaroo thorn | lantana - lantana camara | lincoln weed, sand rocket or mustard | mallee catchfly | medic | messmate stringybark | mimosa pigra | mistflower or creeping crofton weed | narrowleaf peppermint | new zealand spinach | noogoora burr | onion or guildford grass | parthenium weed | paterson's curse | prickly lettuce | privet | ragwort | red pigweed (

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - iprodione - suspension concentrate - iprodione carbamate active 500.0 g/l - fungicide - almond | apple | boysenberry | celery | grape | kiwi fruit | lettuce | lucerne | macadamia | mandarin (non-bearing) | ornamental - alternaria leaf spot - alternaria spp. | alternata spot | black leaf blight | blossom blight - monilinia fructicola | blossom blight - monilinia laxa | blossom blight - sclerotinia spp. | botrytis | brown fruit rot - monilinia fructicola | brown rot - monilinia spp. | grey mould - botrytis cinerea | hypocotyl rot on potato | leptosphaerulina leaf spot | lucerne leaf spot | sclerotinia dropcollar rot of lettuce | sclerotinia wilt or stem rot | storage fruit rot | target spot - alternaria solani | transit rot - suppression | black scurf | blossom blight | botrytis blight | botrytis rot | botrytis spp | brown rot | bunch rot | bunch rot-grey mould | gloeosporium spp | grey mould | grey mould (nesting) | pink rot | post-harvest rot | sclerotinia nest | sclerotinia rot | storage rot | watery soft rot | white mould